Data published in the lancet oncology indicate men with prostate cancer treated with the accuray cyberknife® platform experienced a lower incidence of bladder side effects than those treated with conventional linear accelerators

Latest research published in the lancet oncology: suggests bladder side effects were experienced half as often with cyberknife sbrt as with conventional linear accelerator delivered sbrt two years after treatment almost 20 years of global clinical data: shows the non-surgical cyberknife platform provides excellent disease control with low rates of toxicity for men with prostate cancer sunnyvale, calif. , oct. 11, 2022 /prnewswire/ -- accuray incorporated (nasdaq: aray) announced today that results of the pace-b – prostate advances in comparative evidence – trial were published in the lancet oncology , a leading global peer-reviewed oncology journal.
ARAY Ratings Summary
ARAY Quant Ranking